First Trust Nasdaq Pharmaceuticals ETF
FTXH
32 hedge funds and large institutions have $18.9M invested in First Trust Nasdaq Pharmaceuticals ETF in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 3 closing their positions.
200% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 3
59% more capital invested
Capital invested by funds: $11.9M → $18.9M (+$6.98M)
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
23% more funds holding
Funds holding: 26 → 32 (+6)
9.16% more ownership
Funds ownership: 55.6% → 64.76% (+9.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Truist Financial
Charlotte,
North Carolina
|
+$1.95M |
| 2 |
OC
Oppenheimer & Co
New York
|
+$1.39M |
| 3 |
LPL Financial
San Diego,
California
|
+$1.08M |
| 4 |
NP
Nilsine Partners
Greenwood Village,
Colorado
|
+$927K |
| 5 |
AIP
Ameritas Investment Partners
Lincoln,
Nebraska
|
+$409K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$528K |
| 2 |
FLPIM
F.L. Putnam Investment Management
Lynnfield,
Massachusetts
|
-$230K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$113K |
| 4 |
KAS
Kestra Advisory Services
Austin,
Texas
|
-$58.9K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$29K |
FTXH Hedge Fund Activity: Q1 2026 in Review
32 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q1 2026, worth a combined $18.9M — up 59% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new FTXH positions and 3 closed out — a net gain of 6 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Truist Financial, opening a new position worth an estimated $1.95M. The largest seller was Old Mission Capital, exiting entirely with an estimated $528K sold.
- 32 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q1 2026, up from 26 in Q4 2025.
- Funds reported $18.9M of First Trust Nasdaq Pharmaceuticals ETF stock for Q1 2026, up 59% quarter-over-quarter.
- 9 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q1 2026 and 3 closed out, a net change of +6 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q1 2026 was Truist Financial, an estimated $1.95M added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q1 2026 was Old Mission Capital, an estimated $528K sold.
Based on aggregated 13F filings for Q1 2026.